Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 200mg | Correction | ||
| Q2 2024 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 25mg | Correction | ||
| Q2 2024 | ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q2 2024 | ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | SYSTEM | NA | Correction | ||
| Q2 2024 | AMMONIA SOLUTION | ORAL | CAPSULE, LIQUID FILLED | NA | Deletion | ||
| Q2 2024 | ANHYDROUS CITRIC ACID | ORAL | TABLET, FILM COATED | 4.50 mg | 27mg | Deletion | |
| Q2 2024 | ASPARTAME | ORAL | SUSPENSION | 50.00 mg/ 5.00 ml | 420mg | Deletion | |
| Q1 2024 | ANHYDROUS CITRIC ACID | NASAL | SPRAY | 26.03 mg/ 1.00 ml | MDE Replacement | ||
| Q2 2024 | ANHYDROUS CITRIC ACID | NASAL | SPRAY | 5mg | MDE Replacement | ||
| Q1 2024 | ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, FOR SUSPENSION | 400.00 mg/ 5.00 ml | MDE Replacement | ||
| Q2 2024 | ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, FOR SUSPENSION | 4000mg | MDE Replacement | ||
| Q1 2024 | ASCORBIC ACID | INTRAMUSCULAR | INJECTION | 0.20 %w/v | MDE Replacement | ||
| Q2 2024 | ASCORBIC ACID | INTRAMUSCULAR | INJECTION | 192mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024